🔎 Trials Near Me

Hjem › Mage-tarmkreft › Massachusetts

Kliniske studier for Mage-tarmkreft i Massachusetts

15 studier for Mage-tarmkreft søker deltakere på steder i Massachusetts.

Byer i Massachusetts

Offisiell studietekst (engelsk)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Dana-Farber Cancer Institute - Oncology Department, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • Brigham and Women's Hospital (BWH), Boston
  • Dana-Farber Cancer Institute (DFCI), Boston
  • Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
  • og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07222800

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

  • GSK Investigational Site, Boston
  • GSK Investigational Site, Boston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07218926

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06128551

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06445062

SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)

  • Dana Farber Cancer Institute, Boston
  • Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
  • Dana-Farber Cancer Instiute - Merrimack Valley, Methuen
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT05375643

Resilience and Equity in Aging, Cancer, and Health (REACH)

  • Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 65 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT04674267

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT04899908

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 27. aug. 2026 · NCT07544589

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Massachusetts General Hospital Cancer Center, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626

BOLSTER: Learning New Skills to Thrive

  • Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 18. jun. 2026 · NCT06936878

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT06040541

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • Massachusetts General Hospital,, Boston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 27. mai 2026 · NCT03093116

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2026 · NCT05379985

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. apr. 2026 · NCT07020221

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.